NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

4832.20 -42.60 (-0.87%)

106.0K NSE+BSE Volume

NSE 03 Jul, 2025 12:37 PM (IST)

57,776.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

14 Feb 2017

4832.20

-0.87%

Result Updates

Accumulate: Alkem Laboratories Ltd.

Recommendation Target

Angel Broking

The stock at the CMP of Rs1,837 is available at P/E of 17.5x of FY19E EPS of `105. The stock price in CY2017 has appreciated by 13% leaving less room for further upside at this juncture. We expect company to report CAGR of 17.4% and 22.4% in top line and bottom line respectively in next two years. Its ANDA pipeline has not seen strong tra..

Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.

Alkem Laboratories Ltd.

11 Feb 2017

4832.20

-0.87%

Alkem (3QFY17): Growth story continues. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Alkem (ALKEM) reported strong numbers in 3QFY17 as the top-line grew by ~16% YoY, helped by a 13.5% growth in India (highest among peers) and ~30% YoY growth in the US (~8% beat). EBITDA margins at 18.1% and earnings growth of ~24%YoY were a positive surprise.

Number of FII/FPI investors increased from 524 to 535 in Mar 2025 qtr.

Alkem Laboratories Ltd.

03 Jan 2017, 12:00AM

4832.20

-0.87%

Alkem Laboratories Ltd

Buy: Alkem Laboratories Ltd.

Angel Broking

Alkem Laboratories is a Mumbai based pharma company engaged in manufacturing and marketing of generic drugs, APIs and neutraceutical products. Company sells its drugs in India and ~50 countries including the US. It has 16 manufacturing facilities of which 14 are in India and two in the USA. The stock at the CMP of Rs1,620 is available at ..

Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.

Alkem Laboratories Ltd.

20 Oct 2016

4832.20

-0.87%

Alkem (Initiating Coverage): Compounding story. BUY

Buy: Alkem Laboratories Ltd.

HDFC Securities

ALKEMs flourishing Indian acute business (65% of rev.) and growing US segment (24% CAGR) provide a strong foundation for another compounding story to unfold from Indian generics. In India, ALKEM has 15 acute brands in top 300 and is the 4th fastest growing company in the last five years. With US revenues likely to grow at a fast clip, ALKEM?s top line (18% CAGR) and profitability improvement ( 280bps) will drive 24% EPS CAGR over FY16-19E.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

13 Aug 2016

4832.20

-0.87%

Alkem Laboratories: Strong overall performance; Margins continued to

Buy: Alkem Laboratories Ltd.

Motilal Oswal

Alkem's net sales for 1QFY17 stood at INR14.6b, up 21% YoY (beat of 3.5%), driven by a strong domestic performance (up 22% YoY) and steady growth in US (up 12% YoY). Despite regulatory headwinds in domestic markets and increase in R&D; to ~5.4% (up 180bps YoY), EBITDA margin was at record high levels at 18.6% (up 150 bps YoY & ~300bps above our est). Strong margin performance was driven by robust growth in India (most profitable division for the company). PAT came at INR2.4b (up 19% YoY) and was positively impacted by lower tax rate at ~9% in 1Q....

Alkem Laboratories L.. has an average target of 5278.50 from 2 brokers.

Alkem Laboratories Ltd.

07 Dec 2015

4832.20

-0.87%

Alkem Laboratories Limited- Research Report

Alkem Laboratories Ltd.

Angel Broking

Alkem Laboratories (Alkem) is among the largest companies in the Indian formulation market, having a market share of 3.6%. The company is the fifth largest pharmaceutical company in India by domestic sales. Currently, domestic markets constitute around 75% of its sales; while in terms of exports, the company is at a relatively nascent stage vis-a-vis its peers. In exports (predominately US), the company is expanding through both the inorganic and the organic route. Alkem has 16 manufacturing units, 14 in India and 2 in the US; of which, 5 are USFDA, TGA and UK-MHRA approved. Established Market Leadership in Domestic formulation market: Alkem is one of Indias leading pharmaceutical companies in the domestic formulation market Domestic formulations constitute around ~75% of the companys overall sales. The company ranks fifth in the Indian pharmaceutical market. Its most significant therapeutic areas accounted for 80.7% of its total sales in the domestic market in FY2015. Its revenues from domestic operations grew at a CAGR of 17.6% over FY2011 to FY2015. Expanding in export markets: Although a late entrant in the export markets, ~25% of Alkems sales are contributed by exports. The company has expanded internationally through organic growth and through certain strategic acquisitions....

Alkem Laboratories Ltd. is trading below all available SMAs

Is Alkem Laboratories Ltd. worth buying?

138 Votes:

Buy 78.99%

Sell 14.49%

Hold 6.52%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf